Financials

  • Market Capitalization 653.87 M
  • Employee 102
  • Founded 2010
  • CEO Brian Stuglik
  • Website www.verastem.com
  • Headquarter Massachusetts, United States
  • FIGI BBG001J2LSK5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.56
Price to sales ratio
17.31

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2746
SGMT
Sagimet Biosciences Inc. - Series A Common Stock
10.55 USD-1.86%+4.25%+49.22%+42.38%655.77 M USD
2748
PRME
Prime Medicine, Inc. - Common Stock
3.61 USD-0.82%+6.80%+18.75%+13.88%654.77 M USD
2756
CRMD
CorMedix Inc. - Common Stock
8.30 USD-0.12%+0.73%+14.01%-26.55%646.94 M USD
2764
RGNX
REGENXBIO Inc. - Common Stock
9.66 USD+3.09%+16.53%-0.92%-28.07%637.69 M USD

Frequently asked questions about Verastem, Inc.

What is the Verastem, Inc. stock price today?

The current price of Verastem, Inc. (VSTM) is 7.22. Over the past 24 hours, the stock has changed by -2.17%. Follow the VSTM chart for real-time price dynamics.

What is the stock ticker of Verastem, Inc.?

Verastem, Inc. trades under the ticker VSTM. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Verastem, Inc. stock going up?

VSTM has changed by +4.64% over the last week, +21.96% over the last month, and -19.78% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Verastem, Inc.?

Verastem, Inc. currently has a market capitalization of 653.87 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Verastem, Inc. earnings last quarter?

Last quarter, Verastem, Inc. reported earnings of -0.35 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Verastem, Inc. revenue for the last quarter?

Verastem, Inc. reported quarterly revenue of 40.08 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Verastem, Inc. net income for the last quarter?

Verastem, Inc. reported net income of -34.67 M for the last quarter. The previous quarter showed -36.59 M, which means net income changed by +5.24%.

How many employees does Verastem, Inc. have?

As of the latest available data, Verastem, Inc. has 102 employees. Workforce size can provide additional context about the company's scale and operations.

What is Verastem, Inc. EBITDA?

Verastem, Inc. EBITDA is -31.99 M, and its EBITDA margin is -79.81%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Verastem, Inc. stock?

You can buy Verastem, Inc. (VSTM) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Verastem, Inc. stock?

Investing in Verastem, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the VSTM chart and related analysis on metatrader.com as part of your research.

Verastem, Inc. - Common Stock

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

News